ISN-001 by Anterogen for Burns: Likelihood of Approval
ISN-001 is under clinical development by Anterogen and currently in Phase II for Burns. According to GlobalData, Phase II drugs for Burns have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData's report assesses how ISN-001's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.ISN-001 overviewISN-001 (ALLO-ASC) is under development for the treatment of perianal fistula, Crohn’s disease, burn wounds, diabetic foot ulcer, epidermolysis bullosa, severe pneumonia caused by the novel coronavirus infection, lateral epicondylitis, burn injury, tendon injury, and fecal incontinence. It is administered as intravenous infusion. The drug candidate was also under development for the treatment of osteoarthrirtis.Anterogen overviewAnterogen is a pharmaceutical company. The company involves in research, development and marketing of cell therapy products. It offers Cupistem injection, an adipose-derived stem cell therapy product for the treatment of Crohn's fistula; Queencell for the regeneration of subcutaneous adipose tissue; Adipocell for the treatment of depressed scars; and Remodulin injection for the treatment of pulmonary arterial hypertension. The company also provides services such as stem cell banking and analysis service. Anterogen operates in South Korea, where it is headquartered in Geumcheon-gu, Seoul, Republic of Korea (South Korea). For a complete picture of ISN-001's drug-specific PTSR and LoA scores, buy the report here.
ISN-001 is under clinical development by Anterogen and currently in Phase II for Burns.
What's Your Reaction?
